BioCryst Pharmaceuticals, Inc.

NASDAQ: BCRX
$3.97
-$0.03 (-0.8%)
Closing price August 7, 2020
The include BioCryst Pharmaceuticals, Exxon Mobil, Fiat Chrysler Automobiles, Hewlett Packard Enterprise, IAMGOLD, Mallinckrodt and Rockwell Collins.
BioCryst Pharmaceuticals saw its shares make a handy gain on early Tuesday after it released the final results from its mid-stage clinical trial in hereditary angioedema.
The top analyst upgrades, downgrades and initiations seen on Thursday include BioCryst Pharmaceuticals, Cisco Systems, Groupon, SunPower, Tesla and Wells Fargo.
FDA rulings can make or break some companies. 24/7 Wall St. has collected eight key FDA decisions coming up in 2016 or 2017.
These biotech companies 24/7 Wall St. has picked stood out from the rest with big moves over the course of last week.
BioCryst Pharmaceuticals shares were crushed after it announced results from OPuS-2 for the treatment of hereditary angioedema attacks.
For the third straight week, insider selling has been nonexistent, while the insider buyers have taken advantage of the market sell-off.
Jefferies is out with its first group of growth stocks to buy this year, and the list has not only some timely picks, but companies that have been knocked to levels that are providing some of the...
The top analyst calls for Wednesday, January 6, 2016, include Bluebird Bio, Check Point Software, Comcast, Eli Lilly, Hyatt Hotels, Lockheed Martin and Rite Aid.
Pharmaceutical companies generally are involved in the lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk to a great amount of risk...
24/7 Wall St. has collected several big FDA decisions coming up in the month of November.
Friday's top analyst upgrades, downgrades and initiations include AT&T, BioCryst Pharmaceuticals, Eli Lilly, Facebook, Flextronics, Gap and Tesla Motors.
The most recent analyst call by Merrill Lynch for BioCryst Pharmaceuticals may be very misunderstood for what it is.
The health care sector and biotech in particular have been on fire so far in 2015, but some biotech stocks in the group just are not carrying their weight.
Within the past week, two Ebola-related companies are showing renewed optimism for their positions, whether it is securing a contract or raising capital.